"The Company is well advanced in its planning for the next trial of ATL1103 and expects to be in a position to commence the trial by or prior to mid 2012 with interim results potentially available in early to mid 2013."
Whilst i love all the speculation the fact is the paragraph above from the 9/2/2012 announcement.
With regards to funding speculation could go from CR to LajollaCove type funding , to pharma company partnership to closing up shop altogether.
Nooone knows so all this hype and speculation is pie in the sky.
What we do know is this:
Fact 1): ATL1103 expects to be in a position to commence the trial by or prior to mid 2012 with interim results potentially available in early to mid 2013.(And thats only phase2 trial.Phase 3 will proceed after Phase3.
Fact2) noone has any idea with funding and ANP are in need of capital to even get phase2 started.
IMO its either a CR plus consolidation of capital of a convertable note similar to other bios re LaJollaCove type situation.
Cheers
Rob
- Forums
- ASX - By Stock
- PER
- licensing due diligence
licensing due diligence, page-4
-
-
- There are more pages in this discussion • 9 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.9¢ |
Change
-0.046(34.1%) |
Mkt cap ! $80.23M |
Open | High | Low | Value | Volume |
8.7¢ | 9.0¢ | 8.6¢ | $2.082M | 23.82M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 250808 | 8.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.9¢ | 312804 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 250808 | 0.088 |
6 | 1150954 | 0.087 |
10 | 552629 | 0.086 |
12 | 1212962 | 0.085 |
8 | 339890 | 0.084 |
Price($) | Vol. | No. |
---|---|---|
0.089 | 312804 | 3 |
0.090 | 150000 | 2 |
0.092 | 50000 | 2 |
0.095 | 55000 | 1 |
0.096 | 50000 | 2 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
SBW
Shekel Brainweigh reports a 50% revenue increase in its Retail Innovation suite and delivers the first batch of 20 Smart Bays to Hitachi as part of a larger order
LGP
Record revenue of $10.2 million as European demand drives 40% quarterly growth, with $1 million in operating cash inflow and $0.5 million in cost savings forecast
PER (ASX) Chart |